An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor

Documents similaires

• Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD ‐1 Inhibitor Plus TKIs in Combination of TACE for uHCC
  par: Houxiang Ya, et autres
  Publié: (2026)
• Sintilimab plus Anlotinib and Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma (SACH-MPM): A Prospective, Single-arm, Phase II Trial
  par: Huang, Yiyi
  Publié: (2026)
• Comparative Survival of First‐Line Immunotherapy Plus Chemotherapy Versus Immunotherapy Monotherapy in Older Adults With Metastatic Non‐Small Cell Lung Cancer: An Emulated Target Trial Approach
  par: Xiangzhong Xue, et autres
  Publié: (2026)
• Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
  par: Jia Yu, et autres
  Publié: (2025)
• Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial
  par: Benedikt Niedermaier, et autres
  Publié: (2026)